JP2010116413A - 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 - Google Patents
近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 Download PDFInfo
- Publication number
- JP2010116413A JP2010116413A JP2010014564A JP2010014564A JP2010116413A JP 2010116413 A JP2010116413 A JP 2010116413A JP 2010014564 A JP2010014564 A JP 2010014564A JP 2010014564 A JP2010014564 A JP 2010014564A JP 2010116413 A JP2010116413 A JP 2010116413A
- Authority
- JP
- Japan
- Prior art keywords
- dye
- general formula
- compound according
- groups
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002405 diagnostic procedure Methods 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 230000000007 visual effect Effects 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 229920002521 macromolecule Polymers 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Chemical class 0.000 claims description 4
- 239000005017 polysaccharide Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 2
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 2
- 102000005600 Cathepsins Human genes 0.000 claims description 2
- 108010084457 Cathepsins Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 2
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 2
- 102000015439 Phospholipases Human genes 0.000 claims description 2
- 108010064785 Phospholipases Proteins 0.000 claims description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 102000005262 Sulfatase Human genes 0.000 claims description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 2
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 230000002366 lipolytic effect Effects 0.000 claims description 2
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229950000688 phenothiazine Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 108060007951 sulfatase Proteins 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 150000004043 trisaccharides Chemical class 0.000 claims description 2
- 229940075420 xanthine Drugs 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 claims 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000012502 diagnostic product Substances 0.000 abstract 2
- 230000007547 defect Effects 0.000 abstract 1
- 239000000975 dye Substances 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- -1 Chromomycine Proteins 0.000 description 17
- 239000008363 phosphate buffer Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 238000006862 quantum yield reaction Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 6
- 239000000539 dimer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 3
- ORDGVWFOWIEHDB-UHFFFAOYSA-N 4-(aminomethyl)benzohydrazide Chemical compound NCC1=CC=C(C(=O)NN)C=C1 ORDGVWFOWIEHDB-UHFFFAOYSA-N 0.000 description 3
- WPBZMCGPFHZRHJ-UHFFFAOYSA-N 4-aminobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N)C=C1 WPBZMCGPFHZRHJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 3
- 229960004657 indocyanine green Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KSCXBGRIQVSKJE-UHFFFAOYSA-N 1-(4-hydrazinylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(NN)C=C1 KSCXBGRIQVSKJE-UHFFFAOYSA-N 0.000 description 2
- GDQXMMLQFVXPGA-UHFFFAOYSA-N 4-(hydrazinesulfonyl)benzoic acid Chemical compound NNS(=O)(=O)C1=CC=C(C(O)=O)C=C1 GDQXMMLQFVXPGA-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- KXMMNJQMGILZDB-UHFFFAOYSA-N 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one Chemical compound O=C1C=CC=CN1C(=S)N1C(=O)C=CC=C1 KXMMNJQMGILZDB-UHFFFAOYSA-N 0.000 description 1
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
- SNKDCTFPQUHAPR-UHFFFAOYSA-N 1-fluoropyrimidine-2,4-dione Chemical compound FN1C=CC(=O)NC1=O SNKDCTFPQUHAPR-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-UHFFFAOYSA-N 2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazine-3,5-dione Chemical compound OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- CQWJGMPBDQNEKC-UKCZNJPKSA-N 2-amino-9-n-[(3s,12r,15s,16r)-12-[(2s)-butan-2-yl]-4,7,10,16-tetramethyl-2,5,8,11,14-pentaoxo-3-propan-2-yl-1-oxa-4,7,10,13-tetrazacyclohexadec-15-yl]-4,6-dimethyl-3-oxo-1-n-[(3s,12r,15s,16r)-4,7,10,16-tetramethyl-2,5,8,11,14-pentaoxo-3,12-di(propan-2-yl) Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)CN(C)C(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H]1NC(=O)C1=CC=C(C)C2=C1N=C1C(C(=O)N[C@@H]3C(N[C@@H](C(=O)N(C)CC(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)C(C)C)=O)=C(N)C(=O)C(C)=C1O2 CQWJGMPBDQNEKC-UKCZNJPKSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- ZNCFMBOWBMPEAC-UHFFFAOYSA-N 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane Chemical compound C1OC(=CC)OCC21COC(=CC)OC2 ZNCFMBOWBMPEAC-UHFFFAOYSA-N 0.000 description 1
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C(C(C1=C)=O)=O)=C1O* Chemical compound CC(C(C(C1=C)=O)=O)=C1O* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150050192 PIGM gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010073038 Penicillin Amidase Proteins 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O bleomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- WFSXUTWNNVIIIG-ZPUQHVIOSA-N glutaconaldehyde Chemical compound O\C=C\C=C\C=O WFSXUTWNNVIIIG-ZPUQHVIOSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012023 mustard compounds Substances 0.000 description 1
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical compound NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- MHYFEEDKONKGEB-UHFFFAOYSA-N oxathiane 2,2-dioxide Chemical compound O=S1(=O)CCCCO1 MHYFEEDKONKGEB-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
- C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
- C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
【解決手段】本発明は、近赤外線(NIR線)を用いた生体内診断法および生体外診断法のための、酸不安定性で酵素的に分割可能な化合物、これらの化合物の視覚的診断薬および治療薬としての使用、およびこれらの化合物を含有する診断用薬に関する。
【選択図】なし
Description
(F−L)m−A (I)
[式中、
Fは少なくとも1個の600〜1200nmの吸収最大値を有する染料分子を表わし、
Lは酸不安定性および/または酵素的に分割可能な結合を含有するリンカー構造体を表わし、
mは1〜80の数値であり、
(ここで、mが1〜3の数値である場合には、
Aは少なくとも1個の600〜1200nmの吸収最大値を有する染料分子、抗生作用分子または抗細胞増殖抑制効果分子、生体分子、非生物巨大分子、または化合物:B−(L−W)oまたはD−(L−W)oを表わし、この場合、
Dは非生物巨大分子を表わし、
Bは生体分子を表わし、
Lは前記の意味を表わし、
Wは抗生作用分子または抗細胞増殖抑制効果分子を表わし、
oは1〜20の数値である、
および、mが4〜80の数値である場合には、
Aは生体分子、非生物巨大分子、または化合物:B−(L−W)oまたはD−(L−W)oを表わし、この場合、
D、B、L、Wおよびoは、前記の意味を表わす]で示される化合物によって解決される。
a)薬物動態機序に基づく濃度差および
b)診断の時点までの蛍光量子収率における差異、
によって明白にされる。
ポリメチン染料、テトラピロール染料、テトラアザピロール染料、キサンチン染料、フェノキサジン染料またはフェノチアジン染料。
R1〜R4およびR7〜R10は互いに無関係にフッ素原子、塩素原子、臭素原子、ヨウ素原子またはニトロ基を表わすか、または基:−COOE1、−CONE1E2、−NHCOE1、−NHCONHE1、−NE1E2、−OE1、−OSO3E1、−SO3E1、−SO2NHE1、−E1を表わし、
(ここで、E1およびE2は互いに無関係に水素原子、飽和または不飽和の、分枝鎖状または直鎖状C1〜C50−アルキル鎖を表わし、この場合、鎖またはこれらの鎖の一部は、場合によっては1つまたは複数の芳香族または飽和環状C5〜C6単位または二環状のC10単位を形成してよく、かつこの場合、C1〜C50−アルキル鎖は酸素原子0〜15個および/またはカルボニル基0〜3個によって中断されており、および/またはヒドロキシ基0〜5個、エステル基0〜5個、炭素基0〜3個、アミノ基0〜3個で置換されている)、
およびここで、それぞれ隣接した基R1〜R4および/またはR7〜R10は6員の芳香族炭素環の形成下に互いに結合していてよく、
R5およびR6は互いに無関係に、前記の意味を有する基:−E1、またはC1〜C4−スルホアルキル鎖を表わし、
および/またはR1〜R10はLとの結合を表わし、
Qは断片:
R11は水素原子、フッ素原子、塩素原子、臭素原子、ヨウ素原子またはニトロ基を表わすか、またはE1およびE2が前記の意味を表わす場合に、基:−NE1E2、−OE1または−E1を表わすか、またはLとの結合を表わし、
R12は水素原子、または前記の意味を表わす基:E1を表わし、
bは数値0、2または3である)を表わし、
XおよびYは互いに無関係にO、S、−CH=CH−または断片:
抗生物質:アクラシノマイシン(Aclacinomycin)、アクチノマイシン(Actinomycin)F1、アントラマイシン(Anthramycin)、アザセリン(Azaserin)、ブレオマイシン(Bleomycine)、カクチノマイシン(Cactinomycin)、カルビシン(Carubicin)、カルジノフィリン(Carzinophilin)、クロモマイシン(Chromomycine)、ダクチノマイシン(Dactinomycin)、ダウノルビシン(Daunorubicin)、ドキソルビシン(Doxorubicin)、エピルビシン(Epirubicin)、ムチオマイシン(Mtiomycine)、マイコフェノール酸(Mycophenolsaure)、ノガラマイシン(Nogalamycin)、オリーボマイシン(Olivomycine)、ペプロマイシン(Peplomycin)、プリカマイシン(Plicamycin)、ポルフィロマイシン(Porfiromycin)、ピューロマイシン(Puromycin)、ストレプトニグリン(Streptonigrin)、ツベルシジン(Tubercidin)、ゾルビシン(Zorubicin)、
葉酸−類似体:デノプテリン(Denopterin)、メトスレキサート(Metothrexat)、プテロプテリン(Pteropterin)、トリメトレキサート(Trimetrexat)、
ピリミジン−類似体:アンシタビン(Ancitabin)、アザシチジン(Azacitidin)、6−アザウリジン(Azauridin)、カーモファー(Carmofur)、シタラビン(Cytarabin)、ドキシフルリジン(Doxifluridin)、エノシタビン(Enocitabin)、フロックスリジン(Floxuridin)、5−フルオル(Fluor)−ウラシル(Uracil)、
プリン−類似体:フルダラビン(Fludarabin)、6−メルカプトプリン(Mercaptopurin)、チアミプリン(Thiamiprin)、チオグアニン(Thioguanin)および前記化合物の誘導体、
アルキル化物質:スルホン酸アルキル、アジリジン、エチレンイミン、メチルメラミン、ニトロ尿素、ナイトロフジェンマスタード化合物、
ホルモン作用物質例えばアンドロゲン、抗副腎(Antiadrenale)、抗アンドロゲン物質、抗エストロゲン、エストロゲン、
LH−RH−類似体および黄体ホルモン物質、
ならびに他の細胞増殖抑制効果物質、例えばタクソール(Taxol)およびタクソール(Taxol)誘導体。
G.R.マルチン(Martin)およびR.K.ジェイン(Jain)、Microvascular Research 46, 216〜230 (1993)、
L.E.ゲルベック(Gerweck)およびK.シータラマン(Seetharaman)、Cancer Research 56、1194〜1198(1996)、
K.エンジン(Engin)他、Int. J. Hyperthermia 11(1995)211〜216、
K.エンジン(Engin)他、Int. J.Radiation Oncology Biol. Phys. 29(1994)125〜132、
G.ヘルムリンガー(Helmlinger)他、Nature Medicine 3 (1997) 177〜182。
F.M. Hamer in The Cyanine Dyes and Related Compounds, John Wiley and Sons, New York, 1964;
J.Fabian et al.,Chem.Rev.92 (1992) 1197;
L.A.Ernst et al., Cytometrie 10 (1989) 3〜10;
P.L.Southwick et al., Cytometrie 11 (1990) 418〜430;
R.B.Mujumdar et al., Bioconjugate Chem. 4 (1993)105〜11;
E.Terpetschnig et al., Anal. Biochem. 217 (1994)197〜204;
J.S.Lindsey et al., Tetrahedron 45 (1989) 4845〜66, 欧州特許出願公開第0591820号明細書;
L.Strekowski et al., J. Heterocycl. Chem. 33 (1996) 1685〜1688;
S.R.Mujumdar et al., Bioconjugate Chem. 7 (1996) 356〜362;
M.Lipowska et al., Synth. Commun. 23 (1993) 3087〜94;
E.Terpetschnig et al., Anal. Chim. Acta 282 (1993) 633〜641;
M. MatsuokaおよびT.Kitao, Dyes Pigm. 10 (1988) 13〜22;
N. NarayananおよびG. Patronay, I. Org. Chem. 60 (1995) 2361〜95。
B.M. Mueller et al., Bioconjugate Chem. 1 (1990) 325〜330;
K. Srinivasachar およびD.M. Neville, Biochemistry 28 (1989) 2501〜09;
D.M. Neville et al., J.Biol. Chem. 264 (1989) 14653〜61;
T. Kaneko et al., Bioconjugate Chem. 2 (1991), 133〜41;
B.A. Froesch et al., Cancer Immunol. Immunother. 42 (1996), 55〜63;
J.V.Crivello et al., J.Polymer Sci: Part A: Polymer Chem. 34 (1996) 3091〜3102。
1.5−(1−オキソエチル)−1,1’−(4−スルホブチル)−インドトリカルボシアニン−ナトリウム塩 1 の合成(図1)
4−ヒドラジノフェニルメチルケトンを、4−アミノフェニルメチルケトンから、ジアゾ化し、かつSnCl2 を用いて還元することによって合成する(T.Gorecki et al., J. Heterocyclic Chem. 33 (1996) 1871〜76による)。
元素分析:
計算値:C 61.99 H 6.33 N 3.91 S 8.95
測定値:C 61.73 H 6.49 N 3.80 S 8.78
吸収:λmax(H2O)=748nm(ε=148000 lモル−1cm−1)
2.1. 1と4−カルボキシフェニルスルホニルヒドラジンとの反応
1 0.2g(0.28ミリモル)および4−カルボキシフェニルスルホニルヒドラジン74mg(0.34ミリモル)をメタノール20ml中に溶解し、トリフルオル酢酸5μlを添加し、および室温で18時間攪拌する。溶剤を真空中で蒸発し、残滓を数回ジクロルメタンを用いて洗浄し、かつ生成物を乾燥させる。収量:4 0.21g
2.2. 1と4−アミノ安息香酸ヒドラジドとの反応
1 0.2g(0.28ミリモル)と4−アミノ安息香酸ヒドラジド51mg(0.34ミリモル)とを2.1と同様に反応させる。収量:5 0.20g
2.3. 1と4−(アミノメチル)安息香酸ヒドラジドとの反応
1 0.2g(0.28ミリモル)と4−アミノメチル安息香酸ヒドラジド56mg(0.34ミリモル)とを2.1と同様に反応させる。収量:6 0.22g
(N−ヒドロキシスクシンイミドエステルおよびイソチオシアネート)(図2)
相応するN−ヒドロキシスクシンイミドエステル化合物7を製造するため、ジメチルホルムアミド(DMF)12ml中に4 0.1g(0.1ミリモル)とN−ヒドロキシスクシンイミド(NHS)14mg(0.12ミリモル)とを装入し、室温でDMF1ml中にジシクロヘキシルカルボジイミド23mg(0.11ミリモル)の溶液を添加する。72時間の攪拌後、ジエチルエーテルを用いて生成物を沈殿し、濾別し、かつ新たにDMF/ジエチルエーテルから再沈殿させる。真空乾燥後、得られた生成物(12mg)を後浄化なしで使用する。
4.1.酸不安定性NHS−エステル7を用いた標識化
ホウ酸塩緩衝剤(pH9.2)0.5ml 50mM中抗体1mgに、7(DMF中原液5ミリモル/l)33μlを添加し、室温で1時間攪拌する。非結合染料をNAP−5−カラム上に分離させる(リン酸塩緩衝剤pH7.8、+0.01% NaN3 25mMを用いた溶出)。生成物mAK9.2.27/4−接合体を溶液中4℃で貯蔵する。
蛍光量子収率Q=0.1%(リン酸塩緩衝剤pH7.8中5μモル/l;R.C.ベンソン(Benson)およびH.A.キューズ(Kues)、J. of Chemical and Engineerign Data 22 (1977) 379による、DMSO中Q=13%を有する標準としてのインドシアニングリーンに関する)。
4.2.酸不安定性イソチオシアネート8を用いた標識化
ホウ酸塩緩衝剤(pH9.2)0.5ml 50mM中抗体1mgに、8(DMF中原液5ミリモル/l)6μlを添加し、室温で15分間攪拌する。非結合染料をNAP−5−カラム上に分離させる(リン酸塩緩衝剤pH7.4、+0.01% NaN3 25mMを用いた溶出)。生成物mAK9.2.27/5−接合体を溶液中4℃で貯蔵する。
5.1.対称スピロダイマー10の製造(図3)
3,9−ジエチリデン−2,4,8,10−テトラオキサスピロ−[5.5]ウンデカン(M.クリベロ(Crivello)他、J.Polymer Sci.:A部:Polymer Chem. 34 (1996) 3091〜3102 により合成)0.1g(0.47ミリモル)および6−アミノ−1−ヘキサノール0.11g(0.94ミリモル)を、ジエチルエーテル15ml中で室温で24時間攪拌し、溶剤を真空中で蒸発する。残滓を油ポンプで乾燥させ、後浄化なしで反応させる。
5.2. 6からなる酸不安定性ヒドラゾンリンカー構造を有する染料二量体(11)の製造(図4)
5−カルボキシ−ビス−1,1’−(4−スルホブチル)−インドトリカルボシアニン−ナトリウム塩9 0.1g(0.14ミリモル)を、DMF10ml中でTBTU45mg(0.14ミリモル)およびトリエチルアミン15mgと一緒に30分攪拌し、かつDMF2ml中6 0.14g(0.16ミリモル)を添加する。室温で5時間の攪拌後、ジエチルエーテルを添加することによって生成物を結晶析出させ、濾別し、かつクロマトグラフィー法により浄化する(RP C−18、流展剤 メタノール/リン酸塩緩衝剤pH8 10mM)。凍結乾燥後、メタノール/ジクロルメタンを有する塩を沈殿させる。11 0.13g(59%)が得られる。
pH値7.4;7.0;6.6;6.0および5.0のリン酸塩緩衝剤50mM中4μモル/l濃度の溶液を37℃で保温する。種々の時点で一定部分を取り出し、蛍光量子収率を測定する(SPEX フルオロログ(Fluorolog)スペクトル蛍光計、400ワットXe−ランプ、PM958−検出器、検出器の波長による感度、インドシアニングリーンに関する数値を検量、例4.1.参照)。
ドキソルビシン−ヒドロクロリド20mg(34μモル)および4−(アミノメチル)安息香酸ヒドラジド11mg(68μモル)を、無水メタノール3ml中でトリフルオル酢酸2μlの添加後室温で24時間攪拌する。生成物12を、アセトニトリルを用いて結晶析出させ、遠心分離させ、アセトニトリルを用いて洗浄し、かつ乾燥させる。収量は粗製生成物18mg(24μモル)。
Claims (12)
- 一般式(I):
(F−L)m−A (I)
[式中、
Fは少なくとも1個の600〜1200nmの吸収最大値を有する染料分子を表わし、
Lは酸不安定性および/または酵素的に分割可能な結合を含有するリンカー構造体を表わし、
mは1〜80の数値であり、
(ここで、mが1〜3の数値である場合には、
Aは少なくとも1個の600〜1200nmの吸収最大値を有する染料分子、抗生作用分子または抗細胞増殖抑制効果分子、生体分子、非生物巨大分子、または化合物:B−(L−W)oまたはD−(L−W)oを表わし、この場合、
Dは非生物巨大分子を表わし、
Bは生体分子を表わし、
Lは前記の意味を表わし、
Wは抗生作用分子または抗細胞増殖抑制効果分子を表わし、
oは1〜20の数値である、
および、mが4〜80の数値である場合には、
Aは生体分子、非生物巨大分子、または化合物:B−(L−W)oまたはD−(L−W)oを表わし、この場合、
D、B、L、Wおよびoは、前記の意味を表わす]で示される化合物。 - 一般式(I)中、Fおよび/またはAが、ポリメチン染料、テトラピロール染料、テトラアザピロール染料、キサンチン染料、フェノキサジン染料またはフェノチアジン染料を表わす、請求項1記載の化合物。
- 一般式(I)中、Fおよび/またはAが、シアニン染料、スクアリリウム染料、クロコニウム染料、メロシアニン染料またはオキソノール染料を表わす、請求項1または2記載の化合物。
- 一般式(I)中、Fおよび/またはAが一般式(II):
R1〜R4およびR7〜R10は互いに無関係にフッ素原子、塩素原子、臭素原子、ヨウ素原子またはニトロ基を表わすか、または基:−COOE1、−CONE1E2、−NHCOE1、−NHCONHE1、−NE1E2、−OE1、−OSO3E1、−SO3E1、−SO2NHE1、−E1を表わし、
(ここで、E1およびE2は互いに無関係に水素原子、飽和または不飽和の、分枝鎖状または直鎖状C1〜C50−アルキル鎖を表わし、この場合、鎖またはこれらの鎖の一部は、場合によっては1つまたは複数の芳香族または飽和環状C5〜C6単位または二環状のC10単位を形成してよく、かつこの場合、C1〜C50−アルキル鎖は酸素原子0〜15個および/またはカルボニル基0〜3個によって中断されており、および/またはヒドロキシ基0〜5個、エステル基0〜5個、カルボキシ基0〜3個、もしくはアミノ基0〜3個で置換されている)、
およびここで、それぞれ隣接した基R1〜R4および/またはR7〜R10は6員の芳香族炭素環の形成下に互いに結合していてよく、
R5およびR6は互いに無関係に、前記の意味を有する基:−E1、またはC1〜C4−スルホアルキル鎖を表わし、
および/またはR1〜R10はLとの結合を表わし、
Qは断片:
R11は水素原子、フッ素原子、塩素原子、臭素原子、ヨウ素原子またはニトロ基を表わすか、またはE1およびE2が前記の意味を表わす場合に、基:−NE1E2、−OE1または−E1を表わすか、またはLとの結合を表わし、
R12は水素原子、または前記の意味を表わす基:E1を表わし、
bは数値0、2または3である)を表わし、
XおよびYは互いに無関係に基:O、S、−CH=CH−または断片:
- 一般式(I)中で、WまたはAが抗生物質、葉酸−類似体、ピリミジン−類似体、プリン−類似体、ホルモン作用物質ならびに他の細胞増殖抑制効果物質を表わす、請求項1から4までのいずれか1項記載の化合物。
- 一般式(I)中、Lが酵素的に分割可能な化学結合を含有する構造体を表わす、請求項1から6までのいずれか1項記載の化合物。
- 一般式(I)中、Lが、カテプシン、ペプチダーゼ、カルボキシペプチダーゼ、α−グルコシダーゼおよびβ−グルコシダーゼ、脂肪分解酵素、ホスホリパーゼ、ホスファターゼ、ホスホジエステラーゼ、蛋白質分解酵素、エラスターゼ、スルファターゼ、還元酵素および細菌性酵素によって分割される構造体を表わす、請求項1から7までのいずれか1項記載の化合物。
- 一般式(I)中、Aおよび/またはBが抗体、抗体の接合体および断片、特異ペプチドおよびタンパク質、受容体、酵素、酵素基質基、ヌクレオチド、天然または合成のリボ核酸またはデオキシリボ核酸、またはこれらの化学変性物、例えばアプタマー(Aptamer)またはアンチセンスオリゴヌクレオチド、リポタンパク質、レクチン、炭水化物、単糖類、二糖類または三糖類、線状または分枝鎖状オリゴ糖または多糖またはオリゴ糖誘導体または多糖誘導体、またはデキストランを表わす、請求項1から8までのいずれか1項記載の化合物。
- 一般式(I)中、Dがポリエチレングリコール、ポリプロピレングリコール、ポリリシンまたはポリリシン−デンドリマー(Dendrimer)またはこれらの誘導体を表わす、請求項1から9までのいずれか1項記載の化合物。
- NIR線を用いた、発病した組織範囲の生体内診断法のため、ならびに発病した組織範囲の治療のための、請求項1による化合物の使用。
- 少なくとも1つの請求項1による化合物と一緒に常用の助剤および/または担体物質ならびに希釈剤を含有する、NIR線を用いた、発病した組織範囲の生体内診断法のための視覚による診断薬。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19717904A DE19717904A1 (de) | 1997-04-23 | 1997-04-23 | Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54471598A Division JP5118790B2 (ja) | 1997-04-23 | 1998-04-02 | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010116413A true JP2010116413A (ja) | 2010-05-27 |
Family
ID=7827982
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54471598A Expired - Fee Related JP5118790B2 (ja) | 1997-04-23 | 1998-04-02 | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 |
JP2010014564A Pending JP2010116413A (ja) | 1997-04-23 | 2010-01-26 | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54471598A Expired - Fee Related JP5118790B2 (ja) | 1997-04-23 | 1998-04-02 | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6534041B1 (ja) |
EP (1) | EP0988060B1 (ja) |
JP (2) | JP5118790B2 (ja) |
KR (1) | KR100613306B1 (ja) |
CN (1) | CN1253507A (ja) |
AT (1) | ATE364404T1 (ja) |
AU (1) | AU733757B2 (ja) |
CA (1) | CA2287262C (ja) |
CY (1) | CY1106860T1 (ja) |
DE (2) | DE19717904A1 (ja) |
DK (1) | DK0988060T3 (ja) |
ES (1) | ES2289786T3 (ja) |
HU (1) | HU226812B1 (ja) |
NO (1) | NO327495B1 (ja) |
PT (1) | PT988060E (ja) |
WO (1) | WO1998047538A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016512964A (ja) * | 2012-12-21 | 2016-05-12 | オリジナル ジー ビー.ブイ. | 微生物機能性を有する切断可能なコーティング材料 |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
DE19717904A1 (de) * | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
US6592847B1 (en) * | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
US6083486A (en) * | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
US7547721B1 (en) | 1998-09-18 | 2009-06-16 | Bayer Schering Pharma Ag | Near infrared fluorescent contrast agent and fluorescence imaging |
JP2000095758A (ja) | 1998-09-18 | 2000-04-04 | Schering Ag | 近赤外蛍光造影剤および蛍光造影方法 |
DE19917713A1 (de) * | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik |
US7175953B2 (en) | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
US6114350A (en) * | 1999-04-19 | 2000-09-05 | Nen Life Science Products, Inc. | Cyanine dyes and synthesis methods thereof |
FR2793414B1 (fr) * | 1999-05-10 | 2003-05-23 | Centre Nat Rech Scient | Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules |
EP1283728A2 (en) * | 2000-05-23 | 2003-02-19 | Amersham Health AS | Contrast agents |
DE10046215B4 (de) | 2000-09-19 | 2004-04-15 | Institut für Chemo- und Biosensorik Münster e.V. i.Ins. | Fluorochrome und deren Verwendung |
US7597878B2 (en) * | 2000-09-19 | 2009-10-06 | Li-Cor, Inc. | Optical fluorescent imaging |
US6716413B1 (en) * | 2000-10-16 | 2004-04-06 | Mallinckrodt, Inc. | Indole compounds as tissue-specific exogenous optical agents |
US20070092450A1 (en) * | 2000-10-16 | 2007-04-26 | Mallinckrodt Inc. | Tissue-specific exogenous optical agents |
US20040180809A1 (en) * | 2000-10-16 | 2004-09-16 | Mallinckrodt Inc. | Tissue-specific exogenous optical agents |
US6673334B1 (en) * | 2000-10-16 | 2004-01-06 | Mallinkcrodt, Inc. | Light sensitive compounds for instant determination of organ function |
US7383076B2 (en) | 2000-11-27 | 2008-06-03 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
US6984373B2 (en) | 2000-12-23 | 2006-01-10 | Dyax Corp. | Fibrin binding moieties useful as imaging agents |
US20030044353A1 (en) * | 2001-01-05 | 2003-03-06 | Ralph Weissleder | Activatable imaging probes |
US20030031627A1 (en) * | 2001-07-31 | 2003-02-13 | Mallinckrodt Inc. | Internal image antibodies for optical imaging and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
AU2003278807A1 (en) | 2002-03-01 | 2004-08-13 | Bracco International B.V. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
ES2506142T3 (es) | 2002-03-01 | 2014-10-13 | Dyax Corp. | Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico |
AU2003225763A1 (en) * | 2002-03-11 | 2003-09-29 | Visen Medical, Inc. | Optical imaging probes |
GB0208989D0 (en) | 2002-04-19 | 2002-05-29 | Amersham Biosciences Uk Ltd | Methods for measuring enzyme activity |
US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
CA2514131A1 (en) * | 2003-01-24 | 2004-08-05 | Schering Ag | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis |
HUE039154T2 (hu) | 2003-03-03 | 2018-12-28 | Dyax Corp | HGF receptort (cMet) specifikusan kötõ peptidek és alkalmazásaik |
US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
JP2005170812A (ja) * | 2003-12-09 | 2005-06-30 | Konica Minolta Medical & Graphic Inc | 蛍光造影剤及び蛍光造影方法 |
US7018775B2 (en) * | 2003-12-15 | 2006-03-28 | Eastman Kodak Company | Infrared absorbing N-alkylsulfate cyanine compounds |
CN101203248A (zh) * | 2005-06-21 | 2008-06-18 | 马林克罗特公司 | 光学成像造影剂 |
WO2007005491A1 (en) * | 2005-06-30 | 2007-01-11 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
US8227621B2 (en) * | 2005-06-30 | 2012-07-24 | Li-Cor, Inc. | Cyanine dyes and methods of use |
EP1745739A3 (en) * | 2005-07-14 | 2009-04-22 | Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt | Optical imaging of rheumatoid arthritis |
WO2007028118A2 (en) | 2005-09-02 | 2007-03-08 | Visen Medical, Inc. | Nicotinic acid and picolinic acid derived near-infrared fluorophores |
US7947256B2 (en) * | 2005-09-02 | 2011-05-24 | Visen Medical, Inc. | Biocompatible fluorescent imaging agents |
AU2006284565B2 (en) | 2005-09-02 | 2013-05-30 | Visen Medical, Inc. | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels |
DE102006029454A1 (de) | 2005-12-05 | 2007-06-06 | Dyomics Gmbh | Hydrophile Marker auf Basis von diasteromeren |
WO2007136413A2 (en) | 2005-12-22 | 2007-11-29 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
US20070148094A1 (en) * | 2005-12-22 | 2007-06-28 | Uzgiris Egidijus E | Polymeric imaging agents and medical imaging methods |
US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
US9201063B2 (en) * | 2006-11-16 | 2015-12-01 | General Electric Company | Sequential analysis of biological samples |
US7629125B2 (en) | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
JP5364589B2 (ja) | 2006-12-11 | 2013-12-11 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 診断および治療適用用フィブリン結合ペプチドコンジュゲート |
DK2118206T3 (en) | 2007-02-09 | 2018-06-18 | Visen Medical Inc | POLYCYCLOF COLORS AND APPLICATION THEREOF |
WO2008109832A2 (en) * | 2007-03-08 | 2008-09-12 | Visen Medical, Inc. | Viable near-infrared fluorochrome labeled cells and methods of making and using same |
US7906106B2 (en) * | 2007-06-27 | 2011-03-15 | General Electric Company | In vivo cell trafficking |
US8021647B2 (en) * | 2007-06-29 | 2011-09-20 | General Electric Company | In vivo optical imaging |
EP3320923B1 (en) | 2008-01-18 | 2022-04-06 | Visen Medical, Inc. | Fluorescent imaging agents |
EP2265630B1 (en) | 2008-04-14 | 2014-10-29 | The General Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
US7951959B2 (en) | 2008-09-17 | 2011-05-31 | Thermo Fisher Scientific (Milwaukee) LLC | Hydrophilic labels for biomolecules |
WO2010057944A1 (en) * | 2008-11-20 | 2010-05-27 | Ge Healthcare As | Dye conjugate imaging agents |
US8864821B2 (en) * | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
WO2010121163A2 (en) * | 2009-04-17 | 2010-10-21 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
US20110021908A1 (en) | 2009-05-27 | 2011-01-27 | Lumicell Diagnostics, Inc. | Methods and systems for spatially identifying abnormal cells |
US9155471B2 (en) | 2009-05-27 | 2015-10-13 | Lumicell, Inc'. | Methods and systems for spatially identifying abnormal cells |
CA2766861A1 (en) | 2009-07-09 | 2011-01-13 | F. Hoffmann-La Roche Ag | In vivo tumor vasculature imaging |
WO2011012646A2 (en) | 2009-07-28 | 2011-02-03 | F. Hoffmann-La Roche Ag | Non-invasive in vivo optical imaging method |
US8401618B2 (en) | 2009-08-28 | 2013-03-19 | Visen Medical, Inc. | Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique |
WO2011038006A1 (en) | 2009-09-22 | 2011-03-31 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
US9677125B2 (en) * | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
KR20130036012A (ko) | 2010-05-07 | 2013-04-09 | 에프. 호프만-라 로슈 아게 | 생체외 세포의 검출을 위한 진단 방법 |
US10350308B2 (en) * | 2010-06-30 | 2019-07-16 | Case Western Reserve University | Molecular probes for imaging myelin |
US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
US9012242B2 (en) | 2010-09-20 | 2015-04-21 | Caliper Life Sciences | Multivalent fluorescent probes |
WO2012054784A1 (en) | 2010-10-20 | 2012-04-26 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
EP2633080B1 (en) | 2010-10-29 | 2018-12-05 | President and Fellows of Harvard College | Method of detecting targets using fluorescently labelled nucleic acid nanotube probes |
WO2012061403A1 (en) * | 2010-11-02 | 2012-05-10 | Life Technologies Corporation | Modified hydrocyanine dyes for the detection of reactive oxygen species |
US9314304B2 (en) | 2010-12-08 | 2016-04-19 | Lumicell, Inc. | Methods and system for image guided cell ablation with microscopic resolution |
US10053447B2 (en) | 2010-12-21 | 2018-08-21 | Pierce Biotechnology, Inc | Fluorescent compounds |
EP2683290B1 (en) | 2011-03-07 | 2018-11-07 | F.Hoffmann-La Roche Ag | Methods for in vivo testing of therapeutic antibodies |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
WO2012131345A2 (en) | 2011-03-25 | 2012-10-04 | Almac Sciences (Scotland) Limited | Enzyme assays |
WO2012154885A2 (en) | 2011-05-09 | 2012-11-15 | Visen Medical, Inc. | Carbonic anhydrase targeting agents and methods of using same |
ES2718812T3 (es) * | 2011-07-11 | 2019-07-04 | Us Health | Conjugados de anticuerpo-fluoróforo fotosensibilizantes |
US8889884B1 (en) | 2011-07-14 | 2014-11-18 | Pierce Biotechnology, Inc. | Phosphine derivatives of fluorescent compounds |
US9249307B2 (en) | 2011-08-16 | 2016-02-02 | Pierce Biotechnology, Inc. | Benzocyanine compounds |
WO2013052776A1 (en) * | 2011-10-07 | 2013-04-11 | Cedars-Sinai Medical Center | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties |
US9751868B2 (en) | 2012-02-28 | 2017-09-05 | Pierce Biotechnology, Inc. | Benzocyanine compounds |
EP2804860B1 (en) | 2012-03-02 | 2016-06-15 | Pierce Biotechnology, Inc. | Indole derivatives as labeling dye for biomolecule |
CN114042171A (zh) | 2012-03-30 | 2022-02-15 | 文森医学公司 | 细菌成像剂及其使用方法 |
EP2831179B1 (en) | 2012-03-30 | 2016-04-20 | Life Technologies Corporation | Modified nucleic acid binding cyanine dyes for the detection of reactive oxygen species |
US9371362B2 (en) | 2012-08-15 | 2016-06-21 | Visen Medical, Inc. | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
WO2014035712A1 (en) | 2012-08-28 | 2014-03-06 | Pierce Biotechnology, Inc. | Benzopyrylium compounds |
WO2014062716A1 (en) | 2012-10-15 | 2014-04-24 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
CN104704366B (zh) | 2012-10-24 | 2018-06-19 | 贝克顿·迪金森公司 | 异羟肟酸取代的氮杂吲哚啉-花菁染料和它的生物共轭物 |
WO2014165216A1 (en) * | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Diagnosing and treating cancer |
WO2014152389A1 (en) | 2013-03-14 | 2014-09-25 | Lumicell, Inc. | Imaging agent for detection of diseased cells |
CN105228628B (zh) | 2013-03-15 | 2019-10-18 | 普渡研究基金会 | 与用于使肿瘤靶向成像的化合物缀合的氨基酸连接基的合成和组合物 |
EP2970674B1 (en) | 2013-03-15 | 2018-12-12 | VisEn Medical, Inc. | 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof |
CN105073761B (zh) | 2013-03-15 | 2020-10-20 | 文森医学公司 | 用于体外和体内成像和检测的取代的硅杂蒽阳离子红至近红外荧光染料 |
CN105531377A (zh) | 2013-07-30 | 2016-04-27 | 哈佛学院院长及董事 | 基于dna的定量成像和超分辨成像 |
JP6190534B2 (ja) | 2013-08-22 | 2017-08-30 | ソニー株式会社 | 水溶性蛍光染料又は有色染料及びその使用方法 |
US10471163B2 (en) | 2013-09-13 | 2019-11-12 | The General Hospital Corporation | Activatable fibrin-binding probes |
WO2015103420A1 (en) | 2013-12-31 | 2015-07-09 | Memorial Sloan Kettering Cancer Center | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
EP3094687B1 (en) | 2014-01-16 | 2020-02-12 | Sony Corporation | Water soluble fluorescent or colored dyes |
AU2015229406C1 (en) | 2014-03-11 | 2021-01-07 | President And Fellows Of Harvard College | High-throughput and highly multiplexed imaging with programmable nucleic acid probes |
EP2944326B1 (en) * | 2014-05-16 | 2018-11-21 | Cyanagen Srl | Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases |
SG11201610052TA (en) | 2014-08-08 | 2017-02-27 | Us Health | Photo-controlled removal of targets in vitro and in vivo |
KR20170094268A (ko) | 2014-12-15 | 2017-08-17 | 메모리얼 슬로안-케터링 캔서 센터 | 향상된 신경-결합 선택성을 갖는 고리형 펩티드, 상기 고리형 펩티드와 결합된 나노입자, 및 실시간 생체내 신경 조직 영상화를 위한 이들의 용도 |
US10124111B2 (en) | 2015-02-24 | 2018-11-13 | The Board Of Trustees Of The Leland Stanford Junior University | Small molecule dye for molecular imaging and photothermal therapy |
US11827661B2 (en) | 2015-02-26 | 2023-11-28 | Sony Group Corporation | Water soluble fluorescent or colored dyes comprising conjugating groups |
WO2016138457A1 (en) | 2015-02-26 | 2016-09-01 | Sony Corporation | Phenylethynylnaphthalene dyes and methods for their use |
JP6849599B2 (ja) | 2015-05-11 | 2021-03-24 | ソニー株式会社 | 超明色ダイマーまたはポリマー染料 |
EP3331909A1 (en) | 2015-08-07 | 2018-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer |
WO2017027370A1 (en) | 2015-08-07 | 2017-02-16 | President And Fellows Of Harvard College | Super resolution imaging of protein-protein interactions |
EP3777978A1 (en) | 2015-08-18 | 2021-02-17 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
NZ739780A (en) | 2015-08-18 | 2024-02-23 | Rakuten Medical Inc | Compositions, combinations and related methods for photoimmunotherapy |
CN105199430B (zh) * | 2015-11-05 | 2017-03-22 | 济宁博联生物科技有限公司 | 一种上皮组织染色剂及其制备方法 |
KR20180093961A (ko) | 2015-12-15 | 2018-08-22 | 메모리얼 슬로안-케터링 캔서 센터 | 조직 구별, 예를 들어, 수술 중 시각화를 위한 영상화 시스템 및 방법 |
BR112018070164B1 (pt) | 2016-04-01 | 2022-09-27 | Sony Corporation Of America | Corantes diméricos ou poliméricos ultrabrilhantes |
JP7145079B2 (ja) | 2016-04-01 | 2022-09-30 | ソニーグループ株式会社 | 剛性のスペーシング基を有する超明色ダイマーまたはポリマー染料 |
US9851359B2 (en) | 2016-04-06 | 2017-12-26 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes with spacing linker groups |
EP3455238A1 (en) | 2016-05-10 | 2019-03-20 | Sony Corporation | Ultra bright polymeric dyes with peptide backbones |
EP3455299B1 (en) | 2016-05-10 | 2024-01-17 | Sony Group Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
WO2017197144A1 (en) | 2016-05-11 | 2017-11-16 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
US11377563B2 (en) | 2016-06-06 | 2022-07-05 | Sony Corporation | Ionic polymers comprising fluorescent or colored reporter groups |
EP3491071A1 (en) | 2016-07-29 | 2019-06-05 | Sony Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
BR112019010947A2 (pt) | 2016-11-30 | 2019-10-01 | Univ Cornell | nanopartículas ultrapequenas funcionalizadas por inibidores e métodos das mesmas |
CN110050071A (zh) | 2016-12-09 | 2019-07-23 | 乌尔蒂维尤股份有限公司 | 用于使用标记的核酸成像剂进行多路复用成像的改进方法 |
EP3568689A1 (en) | 2017-01-10 | 2019-11-20 | Sun Chemical Corporation | In-line coating weight and radiant energy exposure measurement |
CN111315415A (zh) | 2017-10-05 | 2020-06-19 | 索尼公司 | 可编程的聚合药物 |
JP2021503450A (ja) | 2017-11-16 | 2021-02-12 | ソニー株式会社 | プログラム可能なポリマー薬 |
EP4137818A1 (en) | 2018-03-19 | 2023-02-22 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
WO2019182766A1 (en) | 2018-03-21 | 2019-09-26 | Sony Corporation | Polymeric tandem dyes with linker groups |
US11989803B2 (en) | 2018-03-30 | 2024-05-21 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3D reconstruction of anatomical organs and inclusions using short-wave infrared (SWIR) projection tomography |
JP2021529194A (ja) | 2018-06-27 | 2021-10-28 | ソニーグループ株式会社 | デオキシリボースを含むリンカー基を有するポリマー色素 |
KR102132885B1 (ko) * | 2018-09-03 | 2020-07-10 | (주)씨바이오멕스 | 생체물질과 연결될 수 있는 양쪽성 형광물질 |
WO2021062176A2 (en) | 2019-09-26 | 2021-04-01 | Sony Corporation | Polymeric tandem dyes with linker groups |
KR102336507B1 (ko) * | 2020-02-21 | 2021-12-06 | 한림대학교 산학협력단 | 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법 |
KR102369155B1 (ko) * | 2020-07-07 | 2022-02-28 | 한림대학교 산학협력단 | 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법 |
CN112062797B (zh) * | 2020-08-19 | 2021-09-21 | 华南理工大学 | 一种二聚体前药及其制备方法和应用 |
EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
CN114748640B (zh) * | 2022-05-06 | 2024-02-09 | 南方医科大学珠江医院 | 一种pH响应性的siRNA递送系统 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03502098A (ja) * | 1988-06-01 | 1991-05-16 | アメリカ合衆国 | 酸性化された細胞内小胞内で開裂可能な蛋白質架橋試薬 |
JPH05238951A (ja) * | 1990-09-17 | 1993-09-17 | Brunswick Corp | モルホリノアントラサイクリンの抗体への化学結合 |
WO1996017628A1 (de) * | 1994-12-07 | 1996-06-13 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Verfahren zur in-vivo-diagnostik mittels nir-strahlung |
JPH11504656A (ja) * | 1995-10-11 | 1999-04-27 | インスティテュート フューア ディアグノスティクフォルシュンク ゲゼルシャフト ミット ベシュレンクテル ハフツング アン デル フライエン ウニベルジテート ベルリン | ポリメチン染料をロードされたコロイド系を含有する近赤外線診断のための造影剤 |
JP2001521530A (ja) * | 1997-04-23 | 2001-11-06 | インスティトゥート フュア ディアグノスティックフォルシュング ゲゼルシャフト ミット ベシュレンクテル ハフツング アン デア フライエン ウニヴェルジテート ベルリン | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU583854B2 (en) * | 1984-09-13 | 1989-05-11 | Cytogen Corporation | Antibody therapeutic agent conjugates |
US5569587A (en) | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes |
JPH07145148A (ja) * | 1992-06-02 | 1995-06-06 | Bio Sensor Kenkyusho:Kk | ポリメチン系化合物およびそれを用いる測定方法 |
GB9310978D0 (en) * | 1993-05-27 | 1993-07-14 | Zeneca Ltd | Compounds |
DE69632244T2 (de) * | 1995-01-30 | 2005-04-14 | Daiichi Pure Chemicals Co. Ltd. | Diagnostisches Markierungsmittel |
US5741657A (en) * | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
IT1276833B1 (it) | 1995-10-09 | 1997-11-03 | Sorin Biomedica Cardio Spa | Coloranti fluorescenti della famiglia della solfo benz e indocianina |
JP2000508709A (ja) * | 1996-04-19 | 2000-07-11 | アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド | スクアラート染料類および蛍光配列決定法におけるそれらの使用 |
DE19649971A1 (de) | 1996-11-19 | 1998-05-28 | Diagnostikforschung Inst | Optische Diagnostika zur Diagnostik neurodegenerativer Krankheiten mittels Nahinfrarot-Strahlung (NIR-Strahlung) |
JP2006519213A (ja) | 2003-02-28 | 2006-08-24 | シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー | 方法 |
-
1997
- 1997-04-23 DE DE19717904A patent/DE19717904A1/de not_active Ceased
-
1998
- 1998-04-02 JP JP54471598A patent/JP5118790B2/ja not_active Expired - Fee Related
- 1998-04-02 CA CA002287262A patent/CA2287262C/en not_active Expired - Fee Related
- 1998-04-02 DE DE59814030T patent/DE59814030D1/de not_active Expired - Lifetime
- 1998-04-02 AT AT98929212T patent/ATE364404T1/de active
- 1998-04-02 WO PCT/DE1998/001001 patent/WO1998047538A2/de active IP Right Grant
- 1998-04-02 PT PT98929212T patent/PT988060E/pt unknown
- 1998-04-02 US US09/403,418 patent/US6534041B1/en not_active Expired - Lifetime
- 1998-04-02 CN CN98804489A patent/CN1253507A/zh active Pending
- 1998-04-02 EP EP98929212A patent/EP0988060B1/de not_active Expired - Lifetime
- 1998-04-02 HU HU0003132A patent/HU226812B1/hu not_active IP Right Cessation
- 1998-04-02 KR KR1019997009757A patent/KR100613306B1/ko not_active IP Right Cessation
- 1998-04-02 DK DK98929212T patent/DK0988060T3/da active
- 1998-04-02 ES ES98929212T patent/ES2289786T3/es not_active Expired - Lifetime
- 1998-04-02 AU AU79057/98A patent/AU733757B2/en not_active Ceased
-
1999
- 1999-10-22 NO NO19995181A patent/NO327495B1/no not_active IP Right Cessation
-
2007
- 2007-09-12 CY CY20071101174T patent/CY1106860T1/el unknown
-
2010
- 2010-01-26 JP JP2010014564A patent/JP2010116413A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03502098A (ja) * | 1988-06-01 | 1991-05-16 | アメリカ合衆国 | 酸性化された細胞内小胞内で開裂可能な蛋白質架橋試薬 |
JPH05238951A (ja) * | 1990-09-17 | 1993-09-17 | Brunswick Corp | モルホリノアントラサイクリンの抗体への化学結合 |
WO1996017628A1 (de) * | 1994-12-07 | 1996-06-13 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Verfahren zur in-vivo-diagnostik mittels nir-strahlung |
JPH11504656A (ja) * | 1995-10-11 | 1999-04-27 | インスティテュート フューア ディアグノスティクフォルシュンク ゲゼルシャフト ミット ベシュレンクテル ハフツング アン デル フライエン ウニベルジテート ベルリン | ポリメチン染料をロードされたコロイド系を含有する近赤外線診断のための造影剤 |
JP2001521530A (ja) * | 1997-04-23 | 2001-11-06 | インスティトゥート フュア ディアグノスティックフォルシュング ゲゼルシャフト ミット ベシュレンクテル ハフツング アン デア フライエン ウニヴェルジテート ベルリン | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016512964A (ja) * | 2012-12-21 | 2016-05-12 | オリジナル ジー ビー.ブイ. | 微生物機能性を有する切断可能なコーティング材料 |
Also Published As
Publication number | Publication date |
---|---|
AU733757B2 (en) | 2001-05-24 |
KR20010020183A (ko) | 2001-03-15 |
HUP0003132A2 (hu) | 2001-01-29 |
NO327495B1 (no) | 2009-07-20 |
CN1253507A (zh) | 2000-05-17 |
AU7905798A (en) | 1998-11-13 |
ATE364404T1 (de) | 2007-07-15 |
DK0988060T3 (da) | 2007-10-15 |
CA2287262A1 (en) | 1998-10-29 |
JP2001521530A (ja) | 2001-11-06 |
WO1998047538A3 (de) | 1999-01-21 |
CY1106860T1 (el) | 2012-05-23 |
NO995181L (no) | 1999-10-22 |
US6534041B1 (en) | 2003-03-18 |
KR100613306B1 (ko) | 2006-08-17 |
EP0988060A2 (de) | 2000-03-29 |
DE59814030D1 (de) | 2007-07-26 |
DE19717904A1 (de) | 1998-10-29 |
JP5118790B2 (ja) | 2013-01-16 |
PT988060E (pt) | 2007-08-17 |
EP0988060B1 (de) | 2007-06-13 |
ES2289786T3 (es) | 2008-02-01 |
NO995181D0 (no) | 1999-10-22 |
WO1998047538A2 (de) | 1998-10-29 |
HU226812B1 (en) | 2009-11-30 |
HUP0003132A3 (en) | 2003-03-28 |
CA2287262C (en) | 2007-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5118790B2 (ja) | 近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体 | |
EP2035505B1 (en) | Optical fluorescent imaging using cyanine dyes | |
EP2630196B1 (en) | Cyanine dyes and their conjugates | |
EP2419478B1 (en) | Fluorescent imaging with substituted cyanine dyes | |
RU2475266C2 (ru) | Оптические агенты визуализации | |
KR20100017102A (ko) | 광학 조영제 | |
CZ2002991A3 (cs) | Konjugáty protilátka-barvivo a farmaceutický prostředek, který je obsahuje | |
JP2012509300A (ja) | 色素コンジュゲートイメージング剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100218 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100218 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130311 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130314 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130826 |